Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (DE:1AEA)
FRANKFURT:1AEA
Holding DE:1AEA?
Track your performance easily
1AEA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€306.00 - €494.00
Previous Close€468
Volume0.00
Average Volume (3M)12.00
Market Cap
€28.70B
Enterprise Value€26.85B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Oct 24, 2024EPS Estimate
€0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.23
Shares Outstanding59,194,488
10 Day Avg. Volume0
30 Day Avg. Volume12
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)6.76
Price to Sales (P/S)76.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue125.95
Enterprise Value/Gross Profit24.22
Enterprise Value/Ebitda-58.87
Forecast
1Y Price Target
€505.18Price Target Upside7.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Argenx Se News
PremiumCompany Announcements
Argenx’s VYVGART Transforming CIDP Treatment
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageVyvgart’s favorable safety will remain a key differentiator, supporting its continued use as the first biologic of choice.
Market PerformanceVisible Alpha consensus estimates project significant sales growth for Vyvgart in CIDP, representing a substantial portion of long-term consensus sales for Argenx.
Product LaunchVyvgart Hytrulo was approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), which is viewed as the second potential blockbuster opportunity for the Vyvgart franchise.
Bears Say
Clinical ResultsNipo's clinESSDAI and ESSDAI doesn't seem competitive vs what has been seen historically.
Efficacy ComparisonUplizna's efficacy looks numerically worse than Vyvgart's, which may limit its attractiveness as a competing therapy.
Market CompetitivenessUplizna's already approved label is not as clean as Vyvgart's, potentially affecting its market competitiveness.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
22.46% Mutual Funds
0.29% Other Institutional Investors
75.65% Public Companies and
Individual Investors
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was €306.00 and its highest was €494.00 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Oct 24, 2024 which is in 14 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Jul 25, 2024. The company reported €0.41 earnings per share for the quarter, beating the consensus estimate of -€0.819 by €1.229.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is €0.16.
How many shares outstanding does Argenx Se have?
Argenx Se has 59,796,272 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of €0.41 in its last earnings report, beating expectations of -€0.819. Following the earnings report the stock price went down -1.86%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Baker Bros Advisors LP. It holds Argenx Se’s shares valued at 48M.
---
Argenx Se Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€505.18 (7.94% Upside)
€505.18 (7.94% Upside)
Blogger Sentiment
Bullish
DE:1AEA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.01%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
1AEA Earnings Call
Q2 2024
0:00 / 0:00
---
1AEA Stock 12 Month Forecast
Average Price Target
€505.18
▲(7.94% Upside)
Technical Analysis
Best Analysts Covering 1AEA
1 Year
1 Year Success Rate
32/35 ratings generated profit
1 Year Average Return
+36.12%
reiterated a buy rating 17 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +36.12% per trade.
---